The scope of this review article will aim to cover the current literature that demonstrates how tumor-derived alterations in energy, amino acid, and lipid metabolism within the TIME mediate CD8+ T cell dysfunction and how targeting these pathways combats resistance to anti-PD-L1/PD-1 treatment. The gene discussed is CD8A; the disease is neoplasm.